LegoChem Biosciences Stock Forecast for 2023 - 2025 - 2030
Updated on 03/28/2024
LegoChem Biosciences Stock Forecast and Price Target
Given the average yearlong price target of ₩83000.00 provided by prominent analysts over the past few months, there is a potential upside of approximately 6.96% from the last closing price in March, 2024 for LegoChem Biosciences's stock if it is reached. This estimation is based on a high estimate of ₩92000.00 and a low estimate of ₩74000.00. If you're not interested in A141080 stock, you may be interested in its competitors.
6.96% Upside
LegoChem Biosciences Fair Value Forecast for 2023 - 2025 - 2030
LegoChem Biosciences's Price has grown in the last four years, jumping from ₩0.00 to ₩0.00 – an increase of 100.00%. In the next year, analysts predict that Fair Value will reach ₩0.00 – an increase of 100.00%. For the next six years, the forecast is for Fair Value to grow by 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
A207940 Stock Forecast | Samsung Biologics | Buy |
7
|
₩830.00k | Buy/Sell | ₩0.00B | 26.51% |
A068270 Stock Forecast | Celltrion | Outperform |
16
|
₩179.50k | Buy/Sell | ₩215.28k | 22.56% |
A091990 Stock Forecast | Celltrion Healthcare | Outperform |
12
|
₩75.90k | Buy/Sell | ₩90.17k | 18.58% |
A196170 Stock Forecast | ALTEOGEN | Outperform |
6
|
₩180.00k | Buy/Sell | ₩83.33k | -22.22% |
A068760 Stock Forecast | Celltrion Pharm | - |
11
|
₩111.40k | Buy/Sell | ₩11.33k | -100.00% |
LegoChem Biosciences Revenue Forecast for 2023 - 2025 - 2030
LegoChem Biosciences's Revenue has grown in the last year, jumping from ₩32.16B to ₩33.41B – an increase of 3.90%. In the following year, the 0 analysts surveyed believe that LegoChem Biosciences's Revenue will decrease by 3.76%, reaching ₩32.16B. According to professionals, by 2030, LegoChem Biosciences's Revenue will have decreased by 2.37%, falling down to ₩32.62B.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
A006280 Stock Forecast | GC Biopharma | Buy |
16
|
₩123.00k | Buy/Sell | ₩146.43k | 17.89% |
A214370 Stock Forecast | Caregen | Outperform |
18
|
₩21.85k | Buy/Sell | ₩50.00k | 128.83% |
A086900 Stock Forecast | Medy-Tox | Outperform |
8
|
₩142.40k | Buy/Sell | ₩335.00k | 159.83% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
A007390 Stock Forecast | NatureCell | - |
0
|
₩7.29k | Buy/Sell | ₩0.00 | -100.00% |
A256840 Stock Forecast | BNC Korea | - |
0
|
₩3.56k | Buy/Sell | ₩0.00 | -100.00% |
A298380 Stock Forecast | ABL Bio | Outperform |
6
|
₩27.65k | Buy/Sell | ₩37.00k | 32.01% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
A214450 Stock Forecast | PharmaResearch | Outperform |
16
|
₩89.20k | Buy/Sell | ₩165.00k | 96.19% |
A293780 Stock Forecast | AptaBio Therapeutics |
0
|
₩7.62k | Buy/Sell | ₩0.00 | -100.00% | |
A182400 Stock Forecast | NKMAX CO. | - |
7
|
₩5.66k | Buy/Sell | ₩0.00 | -100.00% |
LegoChem Biosciences EBITDA Forecast for 2023 - 2025 - 2030
LegoChem Biosciences's EBITDA has increased by 87.60% In the last year, going from ₩-24.66B to ₩-46.26B. For the next year, 0 analysts project LegoChem Biosciences's EBITDA to drop by 46.69%, reaching ₩-24.66B. By 2030, professionals believe that LegoChem Biosciences's EBITDA will decrease by 16.10%, reaching ₩-38.81B – a concerning trend for the company.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
A144510 Stock Forecast | GC Cell | - |
11
|
₩45.95k | Buy/Sell | ₩74.00k | -100.00% |
A041960 Stock Forecast | Komipharm International | - |
6
|
₩4.39k | Buy/Sell | ₩0.00 | -100.00% |
A065660 Stock Forecast | Anterogen.Co.,Ltd. | - |
7
|
₩14.01k | Buy/Sell | ₩0.00 | -100.00% |
LegoChem Biosciences EBIT Forecast for 2023 - 2025 - 2030
In the last year, LegoChem Biosciences's EBIT has grown, increasing from ₩-27.71B to ₩-50.38B – a growth of 81.82%. According to 0 prominent analysts, LegoChem Biosciences's EBIT will fall by 45.00% in the next year, reaching ₩-27.71B. By 2030, professionals believe that LegoChem Biosciences's EBIT will decrease by 16.33%, reaching ₩-42.15B – a concerning trend for the company.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
A115450 Stock Forecast | HLB Therapeutics | - |
6
|
₩9.12k | Buy/Sell | ₩20.77k | -100.00% |
A290650 Stock Forecast | L&C Bio | - |
17
|
₩23.60k | Buy/Sell | ₩0.00 | -100.00% |
A235980 Stock Forecast | MedPacto | - |
4
|
₩15.89k | Buy/Sell | ₩23.00k | -100.00% |
LegoChem Biosciences EPS Price Prediction Forecast for 2023 - 2025 - 2030
LegoChem Biosciences's EPS has grown in the last four years, jumping from ₩-307.00 to ₩0.00 – an increase of 100.00%. In the next year, analysts predict that EPS will reach ₩0.00 – an increase of 100.00%. For the next six years, the forecast is for EPS to grow by 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
A087010 Stock Forecast | Peptron | - |
6
|
₩25.05k | Buy/Sell | ₩35.00k | -100.00% |
A031390 Stock Forecast | Green Cross Cell | - |
14
|
₩38.55k | Buy/Sell | ₩80.00k | -100.00% |
A299660 Stock Forecast | Cellid, | - |
5
|
₩4.27k | Buy/Sell | ₩0.00 | -100.00% |